Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
1(8%)
Results Posted
22%(2 trials)

Phase Distribution

Ph not_applicable
1
8%
Ph phase_3
3
25%
Ph phase_1
1
8%
Ph phase_2
2
17%
Ph phase_4
5
42%

Phase Distribution

1

Early Stage

2

Mid Stage

8

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
1(8.3%)
Phase 2Efficacy & side effects
2(16.7%)
Phase 3Large-scale testing
3(25.0%)
Phase 4Post-market surveillance
5(41.7%)
N/ANon-phased studies
1(8.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

12

all time

Status Distribution
Active(1)
Completed(9)
Other(2)

Detailed Status

Completed9
unknown2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (8.3%)
Phase 22 (16.7%)
Phase 33 (25.0%)
Phase 45 (41.7%)
N/A1 (8.3%)

Trials by Status

active_not_recruiting18%
completed975%
unknown217%

Recent Activity

1 active trials
Showing 5 of 12
active_not_recruitingphase_2

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

NCT02205762
completedphase_1

Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML

NCT02891278
unknownphase_4

PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years

NCT01358201
completedphase_4

Treatment of High Risk Adult Acute Lymphoblastic Leukemia

NCT00853008
completedphase_3

R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma

NCT00137995
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT02205762Phase 2

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

Active Not Recruiting
NCT02891278Phase 1

Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML

Completed
NCT01358201Phase 4

PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years

Unknown
NCT00853008Phase 4

Treatment of High Risk Adult Acute Lymphoblastic Leukemia

Completed
NCT00137995Phase 3

R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma

Completed
NCT02101983Not Applicable

Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML)

Completed
NCT00495287Phase 3

A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML)

Completed
NCT00526175Phase 4

LAL-BR/2001: Study Treatment to Low Risk ALL

Completed
NCT00085709Phase 3

S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML

Completed
NCT00526409Phase 4

LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia

Completed
NCT00526305Phase 4

LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive

Completed
NCT00199186Phase 2

Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)

Unknown

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12